一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint.
A splicing isoform of PD-1 promotes tumor progression as a potential immune checkpoint.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫检查点受体程序性细胞死亡1(PD-1,由PDCD1编码)介导癌症的免疫逃逸,但PD-1剪接异构体是否参与这一过程仍不清楚。在此,我们鉴定了人类PD-1的一种选择性剪接异构体,其携带从内含子2的5'区域保留的28个碱基对延伸(PD-1^28),表达于外周T细胞和TIL(肿瘤浸润淋巴细胞)中。PD-1^28的表达在T细胞活化后被诱导,并受RNA结合蛋白TAF15调控。在功能上,PD-1^28在体外抑制T细胞增殖、细胞因子产生和肿瘤细胞杀伤。在体内,T细胞特异性外源性表达PD-1^28在同基因小鼠肿瘤模型和接种人类肺癌细胞的人源化NOG小鼠中均促进肿瘤生长。因此,我们的研究表明,PD-1^28作为一种免疫检查点发挥作用,并可能参与对免疫检查点阻断治疗的耐药。
The immune checkpoint receptor, programmed cell death 1 (PD-1, encoded by PDCD1), mediates the immune escape of cancer, but whether PD-1 splicing isoforms contribute to this process is still unclear.
Here, we identify an alternative splicing isoform of human PD-1, which carries a 28-base pairs extension retained from 5' region of intron 2 (PD-1^28), is expressed in peripheral T cells and tumor infiltrating lymphocytes. PD-1^28 expression is induced on T cells upon activation and is regulated by an RNA binding protein, TAF15.
Functionally, PD-1^28 inhibits T cell proliferation, cytokine production, and tumor cell killing in vitro. In vivo, T cell-specific exogenous expression of PD-1^28 promotes tumor growth in both a syngeneic mouse tumor model and humanized NOG mice inoculated with human lung cancer cells.
Our study thus demonstrates that PD-1^28 functions as an immune checkpoint, and may contribute to resistance to immune checkpoint blockade therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。